What type of study is this?

This is a Meta-Analysis study (also classified as: Systematic Review).

December 8, 2025BloodOpen Access

Survival and clinical outcomes in patients with myelofibrosis and new or worsening anemia treated with ruxolitinib: A systematic review and meta-analysis

View Full Paper

Ask AI

Bookmark

New or worsening anemia significantly increases mortality risks in patients with myelofibrosis receiving ruxolitinib treatment.
Anemia at baseline or during treatment resulted in over twice the risk of death during follow-up, emphasizing the treatment challenges.
Bayesian meta-analysis assessed various studies, aggregating data from trials and electronic health records on myelofibrosis outcomes.
Patient-reported outcomes highlighted the impact of anemia on survival, suggesting the need for ongoing management strategies in this patient group.

No takes yet. Share an insight, caveat, or question.

Systematic review shows ruxolitinib treatment worsens anemia in myelofibrosis, indicating increased mortality risk and altered dosing.

Vo et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark